Skip to main content

Table 2 Summary of efficacy

From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Subject No. Histological type Duration of treatment (months) PFS (months)a Best overall responsea Change in sum of the diameter (%)a, b Overall survival (months) Reason for discontinuation
Trabectedin group
1 EMCS 15.6 13.0 SD −1 26.4 progression
2 EMCS 8.9 7.4 SD −27 10.4 progression
3 MCS 22.8 22.2* PR −58 23.0* (continued)c
4 MCS 10.8 7.5 SD 1 19.2* progression
5 MCS 11.7 12.5 SD −1 12.5 subject withdrawald
Best supportive care group
6 MCS 0.5 0.5* NE −2 24.2 progression
7 MCS 0.3 0.3 PD 12 6.4 progression
8 MCS 1.0 1.0 PD 46 3.4 progression
  1. MCS Mesenchymal chondrosarcoma, EMCS Extraskeletal myxoid chondrosarcoma, PFS progression-free survival, PR partial response, SD stable disease, NE not evaluable, PD progressive disease
  2. * Censored observation
  3. aAssessed by central radiology imaging review
  4. bThe best change in sum of the diameter of target lesions from baseline
  5. cParticipated in another study for continuing trabectedin treatment after termination of the randomized phase 2 study
  6. dThe subject hoped for different treatment